Patrick Ryan, PhD is Vice President, Observational Health Data Analytics at Janssen Research and Development, where he is leading efforts to develop and apply analysis methods to better understand the real-world effects of medical products. He is an original collaborator in Observational Health Data Sciences and Informatics (OHDSI), a multi-stakeholder, interdisciplinary collaborative to create open-source solutions that bring out the value of observational health data through large-scale analytics. He served as a principal investigator of the Observational Medical Outcomes Partnership (OMOP), a public-private partnership chaired by the Food and Drug Administration, where he led methodological research to assess the appropriate use of observational health care data to identify and evaluate drug safety issues. Patrick has worked in various positions within the pharmaceutical industry at Pfizer and GlaxoSmithKline, and also in academia at the University of Arizona Arthritis Center.
- Amy P. Abernethy, US FDA
- Graeme Archer, GSK R&D
- Jesse Berlin, Johnson & Johnson
- Lawrence Carin, Duke
- Noémie Elhadad, Columbia
- Igor Jurisica, Krembil Research Institute and University of Toronto
- Faisal Khan, AstraZeneca
- Kannan Natarajan, Pfizer
- Amol Navathe, University of Pennsylvania
- Adler Perotte, Columbia
- Patrick Ryan, Janssen Research and Development
- Mary Ann Slack, US Food and Drug Administration (FDA)
- Simon Tavaré, Columbia
- Mihaela van der Schaar, Cambridge
- Li Wang, AbbVie
Countdown to AIPM
AIPM has begun!
Welcome Address — David Madigan, Ph.D., Columbia University
A Perspective on the Promise and Pitfalls of Artificial Intelligence in Clinical Drug Development — Kannan Natarajan, Pfizer Inc.
Machine Learning: Changing the future of healthcare – from next generation clinical trials to individualized treatment effects — Mihaela van der Schaar, University of Cambridge
Discussant — Patrick Ryan, Janssen Research and Development
ML and AI in Clinical Development and Statistical Innovation — Wang Li, AbbVie.
Opportunities for AI in Healthcare — Lawrence Carin, Duke University
- Demissie Alemayehu, Pfizer Inc.
- David Madigan, Columbia University